The resistance tetrad: amino acid hotspots for kinome-wide exploitation of drug-resistant protein kinase alleles.
Acquired resistance to targeted kinase inhibitors is a well-documented clinical problem that is potentially fatal for patients to whom a suitable back-up is not available. However, protein kinase alleles that promote resistance to inhibitors can be exploited experimentally as gold-standards for "on"- and "off"-target validation strategies and constitute a powerful resource for assessing the ability of new or combined therapies to override resistance. Clinical resistance to kinase inhibitors is an evident in all tyrosine kinase-driven malignancies, where high rates of mutation drive tumor evolution toward the insidious drug-resistant (DR) state through a variety of mechanisms. Unfortunately, this problem is likely to intensify in the future as the number of target kinases, approved inhibitors, and clinical indications increase. To empower the analysis of resistance in kinases, we have validated a bioinformatic, structural, and cellular workflow for designing and evaluating resistance at key mutational hotspots among kinome members. In this chapter, we discuss how mutation of amino acids in the gatekeeper and hinge-loop regions (collectively termed the "resistance tetrad") and the DFG motif represent an effective approach for generating panels of DR kinase alleles for chemical genetics and biological target validation.
Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom.
Fiona P
FP
Bailey
Veselin I
VI
Andreev
Department of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, United Kingdom. Electronic address: patrick.eyers@liverpool.ac.uk.
Patrick A
PA
Eyers
D000483:Alleles; D000818:Animals; D055162:Biocatalysis / Q000187:drug effects; D020134:Catalytic Domain; D015195:Drug Design; D004351:Drug Resistance; D006801:Humans; D057927:Hydrophobic and Hydrophilic Interactions; D008958:Models, Molecular; D009154:Mutation; D011487:Protein Conformation; D047428:Protein Kinase Inhibitors / Q000737:chemistry / Q000494:pharmacology*; D011494:Protein Kinases / Q000737:chemistry / Q000235:genetics* / Q000378:metabolism; D040901:Proteomics / Q000379:methods; D011994:Recombinant Proteins / Q000737:chemistry / Q000378:metabolism; D013379:Substrate Specificity; D013499:Surface Properties
D047428:Protein Kinase Inhibitors; D011994:Recombinant Proteins; D011494:Protein Kinases
ATP; Cancer; Drug; Gatekeeper; Hinge; Inhibitor; Kinase; Kinome; Ligand; Mutation; Polypharmacology; Resistance